Vasomotor Menopausal Symptoms (VMS) Treatment Market Size, Share & Trends Analysis Report By Product | Forecast to 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Future Growth Projections For The Vasomotor Menopausal Symptoms (VMS) Treatment Market Size?
The market size for vasomotor menopausal symptoms (vms) treatment has seen robust growth in the recent past. Projected to rise from $17.86 billion in 2024 to $19.01 billion in 2025, it is set to experience a compound annual growth rate (CAGR) of 6.5%. Factors contributing to this growth during the historic period include hormone replacement therapy (hrt), awareness about menopause, advancements in pharmaceuticals, and customer demand.
The market size for treatment of vasomotor menopausal symptoms (vms) is projected to experience significant growth in the coming years, reaching a value of $24.5 billion by 2029, with a compound annual growth rate (CAGR) of 6.5%. This projected growth during the forecast period is primarily driven by factors such as the rise in personalized healthcare, growth in non-hormonal innovations, increased focus on nutritional and dietary interventions, as well as the influence of telemedicine and digital health. The forecast period is also expected to witness key trends such as the usage of natural and alternative treatments, botanical and herbal cures, the presence of support groups for menopause, and the implementation of cognitive behavioral therapy (CBT).
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp
Which Factors Are Steering Growth In The Vasomotor Menopausal Symptoms (VMS) Treatment Market?
The surge in the population undergoing menopause is projected to fuel the expansion of the market for vasomotor menopausal symptom’s treatment. Menopause is an organic biological process signifying the culmination of a woman’s ability to reproduce. It’s a crucial life phase that commonly happens in women between the ages of 45 and 55, with 51 being the average age. The escalating number of women experiencing menopause requiring treatment for symptoms like hot flashes and vaginal dryness is chiefly contributing to the growth of the vasomotor menopausal symptoms (VMS) therapy market. In November 2022, the Cuyuna Regional Medical Center, an organization based in the US, projected that by 2025, women undergoing menopause will reach a staggering number of 1.1 billion due to increased life expectancy. Furthermore, the menopausal population is anticipated to rise by 1.6% yearly until 2060. Hence, the growing menopausal population is propelling the expansion of the vasomotor menopausal symptom’s treatment market.
How Is The Vasomotor Menopausal Symptoms (VMS) Treatment Market Organized By Different Segments?
The vasomotor menopausal symptoms (vms) treatmentmarket covered in this report is segmented –
1) By Drug Class: Antidepressants; Fluoxetine; Paroxetine; Sertraline; Hormone Therapy; Anticonvulsant; Phenytoin; Phenobarbital; Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors); SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors); TCAs (Tricyclic Antidepressants); MAOIs (Monoamine Oxidase Inhibitors); Atypical Antidepressants
2) By Fluoxetine: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Generalized Anxiety Disorder (GAD); Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Generalized Anxiety Disorder (GAD); Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT); Progestin Therapy; Combined Hormonal Therapy (CHT); Testosterone Replacement Therapy (TRT)
6) Anticonvulsant: Hydantoins; Barbiturates; Benzodiazepines; Valproates; Succinimides; Carboxylic Acid Derivatives
7) Phenytoin: Hydantoins
8) Phenobarbital: Barbiturates
9) Other Drug Classes: Antibiotics; Analgesics; Antidiabetics; Antihypertensives; Anticoagulants; Immunosuppressants; Antipsychotics; Antihistamines
What Current And Upcoming Trends Are Shaping The Vasomotor Menopausal Symptoms (VMS) Treatment Market?
Large firms in the vasomotor menopausal symptoms treatment market, such as Astellas Pharma Inc, are introducing products like Veozah to give fresh treatment alternatives and satisfy the unfulfilled medical needs of patients. The introduction of these novel treatments for menopause boast better effectiveness and safety compared to current methods of treatment. For instance, in May 2023, Veozah (fezolinetant) 45 mg once daily, a creation by Japanese pharmaceutical company Astellas Pharma Inc, received clearance from the American federal agency Food and Drug Administration (FDA) for the treatment of varying intensities of menopausal vasomotor symptoms (VMS). Veozah became the first authorized nonhormonal neurokinin 3 (NK3) receptor antagonist to treat VMS related to menopause, creating a hormone-free option that obstructs a brain pathway responsible for regulating these symptoms. This approval has increased the options for women especially those who are not able or wish to avoid hormone therapy, underscoring Veozah’s potential as a novel treatment of menopausal symptoms.
Who Are The Most Influential Companies In The Vasomotor Menopausal Symptoms (VMS) Treatment Market?
Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.
Access The Complete Report Here:
Which Region Dominates The Vasomotor Menopausal Symptoms (VMS) Treatment Market Today?
North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=13051&type=smp
Browse Through More Reports Similar to the Global Vasomotor Menopausal Symptoms (VMS) Treatment Market 2025, By The Business Research Company
Postmenopausal Osteoporosis Treatment Global Market Report 2025
Menopausal Hot Flashes Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/menopausal-hot-flashes-global-market-report
Pms And Menstrual Health Supplements Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
